Affordable Access

Publisher Website

A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.

Authors
Type
Published Article
Journal
Japanese journal of clinical oncology
Publication Date
Volume
44
Issue
8
Pages
765–769
Identifiers
DOI: 10.1093/jjco/hyu080
PMID: 24916336
Source
Medline
Keywords
  • Phase Ii/Iii
  • High Grade
  • Non-Round Cell Tumor
  • Perioperative Chemotherapy
  • Soft-Tissue Sarcoma

Abstract

A randomized Phase II/III trial was planned to commence in March 2014. Perioperative chemotherapy with adriamycin plus ifosfamide is the current standard treatment for T2bN0M0 high-grade non-round cell soft tissue sarcoma. The purpose of this study is to confirm the non-inferiority of perioperative chemotherapy with gemcitabine and docetaxel to adriamycin plus ifosfamide for patients with T2bN0M0 or any TN1M0 non-round cell soft tissue sarcoma in the extremities and body wall. A total of 140 patients will be accrued from 28 Japanese institutions over 6 years. The primary endpoint in the Phase II part is the proportion of completion of pre-operative chemotherapy without progressive disease and overall survival in the Phase III part. The secondary endpoints are progression-free survival, response rate of pre-operative chemotherapy, pathological response rate, proportion of preservation of diseased limbs, disease control rate and proportion of adverse events. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000013175 [http://www.umin.ac.jp/ctr/index.htm].

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments